Fixed-dose drug combination for treatment of tuberculosis

Indian Pediatrics

Volumn 46, Issue 10, 2009, Pages 877-880

  Mathew, Joseph L ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; ISONIAZID PLUS RIFAMPICIN PLUS PYRAZINAMIDE PLUS ETHAMBUTOL; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; BIOEQUIVALENCE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TREATMENT FAILURE; HUMAN; META ANALYSIS; PATIENT COMPLIANCE; PATIENT SATISFACTION; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SHORT SURVEY; SYSTEMATIC REVIEW; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT;

ANTITUBERCULAR AGENTS; DRUG THERAPY, COMBINATION; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT FAILURE; TUBERCULOSIS;

EID: 70350447375     PISSN: 00196061     EISSN: 00196061     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (17)

1. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120: 713-719. (Pubitemid 47176510)
2. Hong Kong Chest Service/British Medical Research Council. Acceptability, compliance, and adverse reactions when isoniazid, rifampin, and pyrazinamide are given as a combined formulation or separately during three-times-weekly antituberculosis chemotherapy. Am Rev Resp Dis 1989; 140: 1618-1622.
3. Blomberg B, Spinaci S, Fourie B, Laing R. The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis. Bull WHO 2001; 79: 61-68. (Pubitemid 32154097)
4. Tuberculosis Coalition for Technical Assistance (TBCTA). International standards for tuberculosis care. Available at http://www.stoptb.org/resource- center/assets/documents/istc-report.pdf. Accessed on 25 August, 2009.
5. Prasad B, Bhutani H, Singh S. Study of the interaction between rifapentine and isoniazid under acid conditions. J Pharm Biomed Anal 2006; 41: 1438-1441. (Pubitemid 43775891)
6. Bhutani H, Singh S, Jindal KC, Chakraborti AK. Mechanistic explanation to the catalysis by pyrazinamide and ethambutol of reaction between rifampicin and isoniazid in anti-TB FDCs. J Pharm Biomed Anal 2005; 39: 892-899. (Pubitemid 41444204)
7. Laserson KF, Kenyon AS, Kenyon TA, Layloff T, Binkin NJ. Substandard tuberculosis drugs on the global market and their simple detection. Int J Tuberc Lung Dis 2001; 5: 448-454. (Pubitemid 32397569)
8. World Health Organization. WHO List of Prequalified Medicinal Products. Available at http://apps.who.int/prequal/. Accessed on 25 August, 2009.
9. Bartacek A, Schütt D, Panosch B, Borek M; Rimstar 4-FDC Study Group. Comparison of a four-drug fixed-dose combination regimen with a single tablet regimen in smear-positive pulmonary tuberculosis. Int J Tuberc Lung Dis 2009; 13: 760-766.
10. Zaka-Ur-Rehman Z, Jamshaid M, Chaudhry A. Clinical evaluation and monitoring of adverse effects for fixed multidose combination against single drug therapy in pulmonary tuberculosis patients. Pak J Pharm Sci 2008; 21: 185-194.
11. Gravendeel JM, Asapa AS, Becx-Bleumink M, Vrakking HA. Preliminary results of an operational field study to compare side-effects, complaints and treatment results of a single-drug short-course regimen with a four-drug fixed-dose combination (4FDC) regimen in South Sulawesi, Republic of Indonesia. Tuberculosis (Edinb) 2003; 83: 183-186. (Pubitemid 36683570)
12. Su WJ, Perng RP. Fixed-dose combination chemotherapy (Rifater/Rifinah) for active pulmonary tuberculosis in Taiwan: a two-year follow-up. Int J Tuberc Lung Dis 2002; 6: 1029-1032.
13. Zhu L, Yan B, Ma W. Controlled clinical study on efficacy of fixed-dose compounds rifater/rifinah in antituberculous chemotherapy. Zhonghua Jie He He Hu Xi Za Zhi. 1998; 21: 645-647.
14. Suryanto AA, van den Broek J, Hatta M, de Soldenhoff R, van der Werf MJ. Is there an increased risk of TB relapse in patients treated with fixed-dose combination drugs in Indonesia? Int J Tuberc Lung Dis 2008; 12: 174-179.
15. Moulding TS, Le HQ, Rikleen D, Davidson P. Preventing drug-resistant tuberculosis with a fixed dose combination of isoniazid and rifampin. Int J Tuberc Lung Dis 2004; 8: 743-748. (Pubitemid 38747151)
16. Nyazema NZ, Rabvukwa P, Gumbo J, Ndudzo P, Chitemerere C. Bioavailability of rifampicin in a separate formulation and fixed dose combination with isoniazid NIH: a case for a fixed dose combination (FDC) for the treatment of tuberculosis. Cent Afr J Med 1999; 45: 141-144.
17. Pillai G, Fourie PB, Padayatchi N, Onyebujoh PC, McIlleron H, Smith PJ, et al. Recent bioequivalence studies on fixed-dose combination anti-tuberculosis drug formulations available on the global market. Int J Tuberc Lung Dis 1999; 3(11 Suppl 3): S309-S316.